TY - JOUR
T1 - A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer
AU - Baggstrom, Maria Q.
AU - Qi, Yingwei
AU - Koczywas, Marianna
AU - Argiris, Athanassios
AU - Johnson, Elizabeth A.
AU - Millward, Michael J.
AU - Murphy, Sara C.
AU - Erlichman, Charles
AU - Rudin, Charles M.
AU - Govindan, Ramaswamy
PY - 2011/10
Y1 - 2011/10
N2 - Background: AT-101 is an oral inhibitor of the antiapoptotic Bcl proteins (Bcl-2, Bcl-XL, Bcl-W, and Mcl-1) and an inducer of the pro-apoptotic proteins noxa and puma. We studied the efficacy of AT-101 in patients with recurrent chemosensitive extensive-stage small cell lung cancer (SCLC). Methods: Patients with recurrent "sensitive" SCLC (defined as no progression during and no disease recurrence
AB - Background: AT-101 is an oral inhibitor of the antiapoptotic Bcl proteins (Bcl-2, Bcl-XL, Bcl-W, and Mcl-1) and an inducer of the pro-apoptotic proteins noxa and puma. We studied the efficacy of AT-101 in patients with recurrent chemosensitive extensive-stage small cell lung cancer (SCLC). Methods: Patients with recurrent "sensitive" SCLC (defined as no progression during and no disease recurrence
KW - AT-101
KW - Extensive-stage small cell lung cancer
KW - Gossypol
UR - http://www.scopus.com/inward/record.url?scp=80052995730&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052995730&partnerID=8YFLogxK
U2 - 10.1097/JTO.0b013e31822e2941
DO - 10.1097/JTO.0b013e31822e2941
M3 - Article
C2 - 21918390
AN - SCOPUS:80052995730
SN - 1556-0864
VL - 6
SP - 1757
EP - 1760
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 10
ER -